Child Neurology PERF Scientific Grant
The 2018 application period is now closed and the application submission deadline was April 1. Awardees will be announced in May. Click here for submission procedures.
To stay informed about the cycle of these grants and other opportunities, join the CNF Partners email list.
Supports clinical or basic science research by a child neurologist or developmental pediatrician early in his/her academic career. The selected investigator will receive a $100,000 grant of $50,000 per year for two years. The PERF Grant is supported fully by PERF.
- The applicant completed training in child neurology or neurodevelopmental disabilities in an ACGME-approved program no more than seven years prior to application.
- The applicant is a legal resident of the United States or Canada
- The applicant is a Junior or Active member of the Child Neurology Society.
- Applicants with current or approved pending NIH funding will be excluded. No NIH grant is allowed, other than an institutional (i.e. K12, T32) or training grant (i.e. NRSA).
Simply for information, click here for the 2018 announcement, application, and FAQ.
Current and Past Grantees
2017 Child Neurology PERF Scientific Grant Recipient
Tracy Gertler, MD, PhD
Ann & Robert H. Lurie Children’s Hospital
Role of Interneurons in KCNT1-associated Epilepsy
Epileptic encephalopathies (EEs) are severe, infantile-onset epilepsies characterized by drug-resistant, pleomorphic seizures and early developmental arrest. Malignant migrating partial epilepsy of infancy (MMPEI) is a type of EE with a uniquely strong genotype-phenotype association. Gain-of-function missense mutations in KCNT1, the gene encoding a sodium-activated potassium channel called Slack, are identified in ~40% of MMPEI patients. There are no approved treatments for MMPEI, but quinidine, an FDA-approved anti-arrhythmic drug and known KCNT1 channel modulator, exerts anticonvulsant effects in MMPEI, whereas conventional anticonvulsants routinely fail. These findings suggest that targeting hyperactive KCNT1 channels has direct therapeutic value, wherein its use is singularly indicated in patients with an identified KCNT1 mutation. Seizures in MMPEI are pathognomonic, as focal and independent hypersychronous neuronal discharges evidence dysfunctional neocortical microcircuits. The hippocampus has been multiply implicated in MMPEI as a region of abnormal pathology in post-mortem analyses, and represents an experimentally-tractable microcircuit within which the precise anatomical location and neuronal identity in which KCNT1 is expressed is unknown. This proposal puts forth that if the target ion channel complement and pathophysiologic neuronal activity in MMPEI can be more precisely ascertained, there is an opportunity for therapeutic targeting of KCNT1.
As a pediatric neurologist with previous training in neurophysiology, the CNF PERF grant represents for me an opportunity to both participate in refining the means by which precise anticonvulsant therapies for genetic epilepsy are identified, and to reengage in the basic neuroscience community focused on ion channel pathophysiology.
2016 Child Neurology PERF Scientific Grant Recipient
Louis Manganas, MD, PhD
Stony Brook University Medical Center
Quantification of neural progenitor cells in new onset pediatric seizures
My research interests focus on neurogenesis, the birth of new neurons, which occurs throughout adulthood in the mammalian brain. Specifically, I’m interested in how neurogenesis may influence the development of epilepsy after a new onset seizure. As a postdoctoral fellow I was able to show that neural stem cells cultured from a mouse brain had a unique metabolic profile using NMR when compared to other brain cells including mature neurons, astrocytes and oligodendrocytes. Furthermore, non-invasive detection of this unique metabolic profile was possible using MRI/MRS in animals and humans thus also allowing for quantitative measurement of mammalian neural stem cells in vivo. Epileptogenesis is defined as the time period between a new onset seizure and a second seizure thus establishing the diagnosis of epilepsy. It is believed that during this time period, epileptic networks are being formed. After a seizure has occurred neural stem cells begin to divide. One theory of epileptogenesis proposes aberrant connections among these newborn neurons leading to epilepsy. Whether the extent of neural stem cell division or proliferation correlates with risk for epilepsy is unknown. About 50% of patients who have had a single seizure will go on to develop epilepsy. Using MRI/MRS along with the unique neural stem cell metabolic profile to quantify neurogenesis may ultimately allow one to non-invasively determine who would be at risk for epilepsy after a seizure.
The CNF PERF Research Grant will provide for an increased understanding of epileptogenic mechanisms as they relate to neural stem cell proliferation and as a result the development of a prognostic biomarker for epilepsy. My goal would be to use this biomarker as a tool to determine who would be at risk for epilepsy after an initial seizure and help develop therapeutics to target neural stem cell proliferation.
2015 PERF Scientific Grant Recipient
Audrey Brumback, MD
University of California San Francisco
Circuit Mechanisms of Autistic Behavior
As I transition from trainee to independent investigator, the funding provided by Child Neurology Foundation PERF Scientific Grant will allow me to use state-of-the-art technologies like optogenetics to attack the most important questions in autism research head-on. Each year, we discover more and more genes associated with autism. But it’s still not clear how changes in a person’s genes cause them to have challenges in social communication. The focus of my work is to determine how different genetic changes associated with autism cause changes in the brain’s circuitry, and how those changes in brain circuitry cause the core symptoms of autism. By understanding how brain regions “talk” to each other in the normal and diseased brain, we will be able to develop novel therapies for difficult-to-treat neurodevelopmental disorders like autism.
2014 PERF Scientific Grant Recipient
Kristin Guilliams, MD
Washington University in St. Louis, School of Medicine, Neurology and Pediatrics
Brain Oxygen Metabolism in Sickle Cell Disease
This award from the Child Neurology Foundation will give a critical foundation to my research career. With this generous funding, I can complete the groundwork for a larger multicenter trial to reduce strokes in children. The Child Neurology Foundation Scientific Research Award will allow me to investigate the underlying mechanisms of stroke in children. I will use non-invasive MRI techniques to measure cerebral blood flow and oxygen metabolism in children with sickle cell disease, one of the highest risk populations for childhood stroke. Right now, we know that transfusions can help prevent strokes in some children. However, because we cannot tell which children would gain the most benefit, almost all children are started on lifelong monthly transfusions, which are a tremendous burden to the patients, their families, and society. I hope to use MRI to improve stroke risk assessment in children with sickle cell disease so that we can decrease the transfusion burden in some children and be aggressive in preventing stroke in others. Ultimately, I hope this research will contribute to the worldwide effort to stop stroke in children.
2013 PERF Scientific Grant Recipient
Nico Dosenbach, MD, PhD
Division of Pediatric Neurology, Washington University School of Medicine
Receiving the 2013 CNF PERF Scientific Research Award represents a great honor. More importantly, it creates the opportunity to initiate a research program aimed at understanding how intensive therapies affect the brains’ of children with brain injury. Greater knowledge of the brain changes caused by practice-based therapies is critical for improving their efficacy. In addition, mapping the relationships between therapies, brain changes and functional outcomes may open up new therapeutic approaches towards enhancing brain recovery. Thus, the 2013 CNF PERF Scientific Research Award will fund MRI brain imaging studies of children with chronic brain injury and one-sided movement deficits undergoing an intensive therapy regimen called constraint-induced movement therapy (CIMT). Advanced functional MRI techniques will be utilized to carefully trace changes in brain function and brain connectivity attributable to the intervention. These changes will then be related to detailed quantifications of motor function. We contend that this approach will advance our understanding of use-dependent neuroplasticity in general and create testable hypotheses about how current treatments could be further improved.